The article “Diagnosis and Management of Diastolic Dysfunction and Heart Failure,” (March 1, 2006, page 841) contained two errors in the first paragraph of page 845. The words dihydropyridine and nondihydropyridine were misspelled. Also, there was an error in describing the indications and relative contraindications for use of these two classes of drugs (dihydropyridine and nondihydropyridine). The sentences should have read as follows: “However, nondihydropyridine calcium channel blockers (e.g., diltiazem [Cardizem]) and verapamil (Calan), should not be used in patients with bradycardia, conduction defects, or severe heart failure caused by left ventricular systolic dysfunction.³⁰ Instead, nondihydropyridines, such as diltiazem and verapamil, should be used for rate control and angina when beta blockers are contraindicated or ineffective.” The article has been corrected online.